FORT WASHINGTON, Pa., Feb. 27, 2017 /PRNewswire/ -- Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that it plans to participate at thefollowing upcoming investor conferences.
Individuals may listen to the live or an archived presentation made at the conference, which will be posted in the investor relations section of the Company's web site at www.impaxlabs.com. This presentation will be archived on the Company's web site for 90 days.
About Impax Laboratories, Inc.Impax Laboratories, Inc. (Impax) is a specialty pharmaceutical company applying its formulation expertise and drug delivery technology to the development of controlled-release and specialty generics in addition to the development of central nervous system disorder branded products. Impax markets its generic products through its Impax Generics division and markets its branded products through the Impax Specialty Pharma division. Additionally, where strategically appropriate, Impax develops marketing partnerships to fully leverage its technology platform and pursues partnership opportunities that offer alternative dosage form technologies, such as injectables, nasal sprays, inhalers, patches, creams, and ointments. For more information, please visit the Company's Web site at: www.impaxlabs.com.
Company Contacts: Mark DonohueInvestor Relations and Corporate Communications (215) 558-4526 www.impaxlabs.com
Logo - http://photos.prnewswire.com/prnh/20150310/180590LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/impax-to-present-at-upcoming-investor-conferences-300413847.html
SOURCE Impax Laboratories, Inc.
Subscribe to our Free Newsletters!
Cyanosis is the bluish or purplish discoloration of the skin and mucus membranes due to lack of ...
Find out about travel shots or vaccination before you travel to your destination country. Travel ...
Hay fever is caused by allergy to pollen and is characterized by runny or blocked nose, sneezing, ...View All